Latest Manufacturing News

Page 10 of 335
Pure Resources has moved its Garnet Hills strategy from concept towards laboratory validation, with heavy rare earths recovered into solution, CNTF fabrics manufactured in-house and garnet meeting key abrasive standards. The milestones remain early-stage, with no quantified rare earth recovery or commercial revenue reported.
Victor Sage
Victor Sage
30 Oct 2026
PARKD has secured two early-stage contracts, added Symal as its exclusive partner in Victoria and South Australia, and lifted pro forma cash to about A$850,000 through a strategic placement. The progress comes against a sharp liquidity squeeze, with just A$53,000 in cash at 30 September and funding equivalent to 0.21 quarters before the raise.
Victor Sage
Victor Sage
30 Oct 2026
Oakridge International reported a $267,000 operating cash outflow for the September quarter, leaving $343,000 in cash and an estimated 1.28 quarters of funding. The healthcare technology company expects collections and customer orders to improve cash flow, while evaluating additional funding and continuing to manage a potential historical claim from Teko International.
Victor Sage
Victor Sage
30 Oct 2026
Australian Bond Exchange generated $1.68 million in positive operating cash flow in Q1 FY27, lifting cash to $1.49 million while repaying $436,000 of borrowings. The result strengthens its balance sheet, though the quarter’s cash inflows included $263,000 in government grants or tax incentives and $150,000 of interest received.
Victor Sage
Victor Sage
30 Oct 2026
Micro-X has reported a sharp improvement in Rover order activity and more than $3 million in annualised cost savings, while redirecting its strategy towards medical CT. The September quarter still consumed $4.4 million in operating cash, leaving funding dependent on further note proceeds, an expected tax refund and milestone receipts.
Victor Sage
Victor Sage
30 Oct 2026
ABx Group has completed its $2 million underwritten share purchase plan, with shareholders subscribing for $1.1 million and the remaining shortfall placed through the underwriter. The raising delivers fresh capital but also adds 95.2 million shares and 238.1 million options across the transaction.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Arafura Rare Earths has moved its Nolans rare earths project from financing decision to early construction, with A$700 million of procurement scope advanced during the September quarter. The company ended the period with A$885 million in cash and term deposits, while major debt and equity funding arrangements remain subject to completion conditions.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Korvest expects its first-half FY27 trading result to come in significantly above the prior corresponding period and ahead of the stronger second half of FY26. The outlook follows record FY26 revenue, a growing order book and major investment in manufacturing capacity.
Victor Sage
Victor Sage
30 Oct 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Carbonxt is forecasting at least A$22 million of FY27 revenue after securing larger customer orders, but the growth plan remains tied to a delayed Kentucky facility and shareholder approval of a proposed balance sheet restructure. Cash stood at just A$0.7 million after a A$1.0 million operating outflow in the September quarter.
Victor Sage
Victor Sage
30 Oct 2026
Tolu Minerals has strengthened its case for an early 2027 Tolukuma restart, reporting record drilling, a 909,000-ounce resource and A$56.5 million in cash. The next test is execution: assays are delayed, plant refurbishment continues and underground development must translate into mineable reserves and ore supply.
Maxwell Dee
Maxwell Dee
30 Oct 2026

Browse the archive

Full archive